WEP Clinical (WEP) is pleased to announce a partnership with Geron Corporation (Geron), a late-stage clinical biopharmaceutical company, to make investigational drug, imetelstat, available to patients through an Expanded Access Protocol (EAP).
EAPs offer an important potential pathway for patients with serious or immediately life-threatening diseases to gain access to investigational medicines for treatment outside of clinical trials, when no other viable treatment options are available.
The imetelstat EAP is a U.S.-only protocol for eligible adult participants diagnosed with lower risk (very low, low, or intermediate risk by IPSS-R) myelodysplastic syndromes (MDS) who are red blood cell (RBC) transfusion dependent, have failed to respond or have lost response or are ineligible for erythropoiesis-stimulating agents (ESAs), and had not received prior treatment with either a hypomethylating agent or lenalidomide and are non-del(5q).
Imetelstat is a novel, first-in-class telomerase inhibitor exclusively owned by Geron and being developed in hematologic malignancies. For more information, visit www.geron.com.
Jas Khera, Managing Director of WEP, said:
“We are proud to be working with Geron on this EAP. We are committed to creating broader treatment access solutions, and this program will help offer a crucial treatment option for eligible MDS patients.”
Health care professionals can inquire for more details about imetelstat and the EAP by emailing WEP at GeronEAP@wepclinical.com. Additional information is also available on www.ClinicalTrials.gov by searching for NCT05937568.
At WEP Clinical, we are With Every Patient, as we believe every patient should have access to treatment! With this as our guiding principle, we have created a market leading, solutions driven, healthcare services company that partners with drug developers to create broader treatment access solutions for patients worldwide. We take pride in the high-quality output and positive customer experience we create while delivering our services. We specialize in the following: Expanded Access and Post-Approval Named Patient Programs; Market Access Solutions; Home Nursing Services for Decentralized Clinical Trials; and Clinical Trial Sourcing. For more information, please visit www.wepclinical.com.